texas oncology more breakthroughs. more victories
Due to facility issues Texas Oncology–Las Colinas will be closed Monday, February 17–Tuesday, February 18 but plans to reopen Wednesday, February 19.  We apologize for any inconvenience. View More Important Notifications x
Request an Appointment

South Texas Clinical Trials

Texas Oncology cancer centers in South Texas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the South Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the South Texas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the South Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the South Texas area and talk to you doctor to determine which clinical trial is right for you.

Biliary Cancer

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: II

Breast Cancer

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Colon Cancer

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I

Colorectal

Title: Phase 2 Study of SR-8541A in Combination with Botensilimab and Balstilimab in Subjects with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Indication: Colorectal

Location: Texas Oncology-Harlingen

Phase: II

Title: Phase 2 Study of SR-8541A in Combination with Botensilimab and Balstilimab in Subjects with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Indication: Colorectal

Location: Texas Oncology-McAllen

Phase: II

Title: Phase 2 Study of SR-8541A in Combination with Botensilimab and Balstilimab in Subjects with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Indication: Colorectal

Location: Texas Oncology-Weslaco

Phase: II

Endometrial Cancer

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: III

Head and Neck Cancer

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: III

Leukemia

Title: Ph2b/3 Study to evaluate and optimization in combo with untreated CLL View

Description: A Prospective Open-Label Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II/III

Title: Ph2b/3 Study to evaluate and optimization in combo with untreated CLL View

Description: A Prospective Open-Label Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II/III

Title: Ph2b/3 Study to evaluate and optimization in combo with untreated CLL View

Description: A Prospective Open-Label Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II/III

Lung Cancer

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Lymphomas

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I/II

Melanoma

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Weslaco

Phase: III

Myelodysplastic Syndrome

Title: STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes View

Description: A randomized double-blind placebo-controlled multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes View

Description: A randomized double-blind placebo-controlled multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes View

Description: A randomized double-blind placebo-controlled multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Weslaco

Phase: II

Myelomas

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Harlingen

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-McAllen

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Weslaco

Phase: II

Ovarian Cancer

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Prostate Cancer

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: II

Rectal Cancer

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: I

Solid Tumors

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: IV

Thrombocytopenia

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)

Indication: Thrombocytopenia

Location: Texas Oncology-McAllen

Phase: III

Texas Oncology-Harlingen

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Phase 2 Study of SR-8541A in Combination with Botensilimab and Balstilimab in Subjects with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Indication: Colorectal

Location: Texas Oncology-Harlingen

Phase: II

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph2b/3 Study to evaluate and optimization in combo with untreated CLL View

Description: A Prospective Open-Label Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II/III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes View

Description: A randomized double-blind placebo-controlled multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Harlingen

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: IV

Texas Oncology-McAllen

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Phase 2 Study of SR-8541A in Combination with Botensilimab and Balstilimab in Subjects with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Indication: Colorectal

Location: Texas Oncology-McAllen

Phase: II

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)

Indication: Thrombocytopenia

Location: Texas Oncology-McAllen

Phase: III

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph2b/3 Study to evaluate and optimization in combo with untreated CLL View

Description: A Prospective Open-Label Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II/III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes View

Description: A randomized double-blind placebo-controlled multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-McAllen

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: IV

Texas Oncology-Weslaco

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Phase 2 Study of SR-8541A in Combination with Botensilimab and Balstilimab in Subjects with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Indication: Colorectal

Location: Texas Oncology-Weslaco

Phase: II

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph2b/3 Study to evaluate and optimization in combo with untreated CLL View

Description: A Prospective Open-Label Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II/III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes View

Description: A randomized double-blind placebo-controlled multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Weslaco

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: IV

No Phase

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: I

Phase I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Phase II

Title: Phase 2 Study of SR-8541A in Combination with Botensilimab and Balstilimab in Subjects with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Indication: Colorectal

Location: Texas Oncology-Harlingen

Phase: II

Title: Phase 2 Study of SR-8541A in Combination with Botensilimab and Balstilimab in Subjects with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Indication: Colorectal

Location: Texas Oncology-McAllen

Phase: II

Title: Phase 2 Study of SR-8541A in Combination with Botensilimab and Balstilimab in Subjects with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Indication: Colorectal

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes View

Description: A randomized double-blind placebo-controlled multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes View

Description: A randomized double-blind placebo-controlled multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes View

Description: A randomized double-blind placebo-controlled multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Weslaco

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Harlingen

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-McAllen

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: II

Phase II/III

Title: Ph2b/3 Study to evaluate and optimization in combo with untreated CLL View

Description: A Prospective Open-Label Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II/III

Title: Ph2b/3 Study to evaluate and optimization in combo with untreated CLL View

Description: A Prospective Open-Label Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II/III

Title: Ph2b/3 Study to evaluate and optimization in combo with untreated CLL View

Description: A Prospective Open-Label Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II/III

Phase III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)

Indication: Thrombocytopenia

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Weslaco

Phase: III

Phase IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: IV